Log in
University of Southampton research into the anti-inflammatory effects of omega-3 fatty acids and the mechanisms by which they act has delivered benefits for the treatment of cardiovascular disease, improving clinical practice, lowering mortality rates and reducing healthcare costs. The findings of a novel mechanism of action by which omega-3 reduces cardiovascular events and mortality have contributed to UK government guidelines on nutrition, have been cited in European atherosclerosis guidelines, and have been patented and licensed in several countries, resulting in new research income. They have also received significant media exposure and formed the basis of a number of educational events for health professionals.
Canine osteoarthritis affects up to 20% of adult dogs and is of worldwide welfare importance. Research by the University of Liverpool (UoL) (with collaborators) has led to profound changes in the ways in which veterinarians manage canine and feline osteoarthritis. Molecular insights have led to new prescription diets that enable veterinarians to improve the health and wellbeing of companion animals and have provided economic impact through sales of these prescription diets. In addition, a new clinical metrology instrument (`Liverpool Osteoarthritis in Dogs' or "LOAD") for assessment of canine osteoarthritis by veterinarians and owners has changed veterinary practice through improved diagnosis, monitoring and management of dogs with osteoarthritis. LOAD has been licensed on a global basis to a pharmaceutical company (Novartis Animal Health).
A new family of antiviral agents, bicyclic nucleoside analogues (BCNAs), discovered in Cardiff University has led to a highly potent anti-VZV (shingles) molecule, FV-100. On a worldwide basis more than two million patients are affected by shingles annually. FV-100 has successfully completed Phase II clinical trials, showing it is safe, potent and effective and with clinical advantages over the current standard of care. FV-100 has received more than $30 million in R&D investment, generating patents and creating highly skilled jobs in the UK and the USA, with the parent company currently valued at $397 million. It will enter registration trials in late 2013.
A Cardiff researcher has led an International 15 year programme resulting in multiple novel findings which have led to changes in the recommended diagnosis and treatment of acquired haemophilia A (AHA). The research has, for the first time, allowed the comparison of immunosuppressive regimens for inhibitor eradication and comparison of the efficacy of treatment strategies to control bleeds. Studies led directly to the production of UK and International guidelines on the management of AHA with 14 of the 18 specific recommendations in the UK guideline being underpinned by Cardiff-led research.
Cardiff University research led to second-generation chemiluminescent technology. The invention allowed for internal amplification control in nucleic-acid based clinical diagnostic assays for infectious disease and produced results with greater accuracy and fulfilled previously unmet regulatory standards. Adopted by the market leader in nucleic acid diagnostics (a sub-licensee of Cardiff University) the Cardiff technology is used globally in more than 60 million in vitro diagnostic tests annually. Sales of the tests approach $500 million per year and the sub-licensee was subsequently sold for $3.8 billion.
Platinum Group Elements (PGE) are critical strategic metals because of their unrivalled applications in catalysts, fuel cells and electronics and cancer therapies. Research and analytical methods developed at Cardiff have impacted on exploration for new PGE deposits, and more efficient processing of PGE ores by international mining companies. A key milestone between 2009 and 2012 was the discovery of a 3 billion year old giant impact crater in West Greenland. This discovery is of major economic significance because all craters previously found in this size class are associated with multi-billion dollar mineral and/or hydrocarbon resources. It led to an intellectual property transaction worth CDN$ 2.1 million and discovery of nickel and PGE deposits in Greenland by North American Nickel Incorporated.
Research and Development activity at Cardiff University's Astronomy Instrumentation Group (AIG) has been commercialised and made available to the international market. Sales have been made to fields including bio-molecular spectroscopy for health science, plasma fusion diagnostics for sustainable energy, and remote atmospheric sensing. This has resulted in economic impact through:
3D scanning technology has enabled multiple opportunities for innovation in diverse areas such as manufacturing, design, and the arts. However, full utilisation of this technology requires not just the scanning hardware, but accompanying software that can build meaningful, editable models. This development has been pioneered by research conducted in the School of Computer Science and Informatics, at Cardiff University. Innovative algorithms for reverse engineering and digital shape reconstruction were devised that enabled the reconstruction of complex computer aided design (CAD) models from data captured by 3D scanners. The algorithms have been endorsed by Geomagic Inc, a market leading American software corporation (recently acquired by 3D Systems), that has subsidiaries in Europe and Asia and global distributors, and incorporated into their software product suite. This is accessed by nearly 10,000 licensed users worldwide, who have applied the product for industrial applications including aerospace and automotive engineering, product design, cultural heritage preservation, and healthcare. Accordingly, the impacts claimed are twofold: a) economic gain manifesting in the benefits to Geomagic and a plethora of end users who have utilised the software, b) impact on practitioners and professional services in diverse domains.
Research by a team at Southampton into amyloid beta protein (A03b2) immunisation to treat Alzheimer's disease has been key to changing the way the global medical community understands and reacts to the disease. The first to observe that A03b2 immunisation clears A03b2 plaques, the team's studies were pivotal in initiating and informing the safe clinical trial development of 40 immunotherapy agents; investments of $3bn by the pharmaceutical industry; and 30 phase II and phase III studies. The research shaped US government policy on new safety measures for clinical trials and played a leading role in the doubling of UK funding to tackle Alzheimer's.
Economic gains by oil and gas companies, improvements in professional practice in hydrocarbon exploration, and environmental benefits from identifying CO2 disposal sites have been achieved through a Cardiff-led consortium with industry. Building on research carried out since 2004, ten of the largest oil companies in the World have contributed to and benefited from understanding how faulted caprocks behave under specific geological conditions. Research at Cardiff has shown which families of faults and fractures make caprocks highly permeable, thus improving Industry's ability to predict if caprocks are able to prevent oil and gas reaching the surface.